Abstract Context Concerns about potential prostate-related complications associated with testosterone replacement therapy (TRT) often lead hypogonadal men to remain untreated. Methods This large-scale retrospective cohort study aimed to address these concerns by analyzing Medicare enrollment and claims data (Parts A/B/C/D) from 2007 to 2020 for men aged ≥65 with diagnosed primary or secondary hypogonadism. Cox regression analysis and 1:1 propensity score matching, both strati

Abstract Background: Centralized locations in the electronic health record (EHR) improve access to advance care planning (ACP) information; however, the prevalence of documentation errors in these locations is unknown. Methods: In this cross-sectional study, we included primary care patients aged ≥65 years or ≥18 years with a serious illness. We verified errors using keyword queries and categorized them as “Patient Safety Errors” (e.g., ACP not in the centralized location)

Abstract Background and objective Several phase 2–4 studies have investigated mirabegron for treating patients with overactive bladder (OAB). The objective of this study was to evaluate the efficacy and safety of mirabegron in adult male OAB patients with or without benign prostate enlargement (BPE) receiving medications for lower urinary tract symptoms (LUTS) management. Methods A post hoc analysis of 13 phase 2–4 studies using mirabegron (2- or 4-wk single-blind placebo run